Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials.

Gili KenetThomas MoultonBrian M WicklundSanjay P AhujaMiguel A Escobar Johnny N Mahlangu

Published in: Journal of blood medicine (2023)

Treatment with octocog alfa prophylaxis appeared to have a favorable risk-benefit profile compared with rFVIII-FS and thus could be an effective and improved alternative strategy for individualized treatment for children, adolescent and adult patients with severe hemophilia A currently on rFVIII-FS treatment.

Keyphrases

clinical trial
mental health
type diabetes
combination therapy
replacement therapy
weight loss
smoking cessation
glycemic control